Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.61 |
| ▸ | NPC1 | O15118 | 6/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | AR | P10275 | 5/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18674668 | 0.88 | AR (0.70) | RAB9ASMN1; SMN2NPC1ALDH1A1POLB | |
| SCHEMBL14183837 | 0.86 | SMN1; SMN2 (0.72) | RAB9ASMN1; SMN2NPC1ALDH1A1POLB | |
| SCHEMBL12669971 | 0.84 | ALDH1A1 (0.56) | RAB9ASMN1; SMN2NPC1ALDH1A1POLB | |
| SCHEMBL12632067 | 0.84 | ALDH1A1 (0.56) | RAB9ASMN1; SMN2NPC1ALDH1A1POLB | |
| SCHEMBL2157208 | 0.84 | ALDH1A1 (0.58) | RAB9ASMN1; SMN2NPC1ALDH1A1POLB | |
| SCHEMBL17536090 | 0.84 | RAB9A (0.60) | RAB9ASMN1; SMN2NPC1POLBMEN1 | |
| SCHEMBL18674640 | 0.84 | AR (0.74) | RAB9ASMN1; SMN2NPC1ALDH1A1MEN1 | |
| SCHEMBL6407201 | 0.83 | ALDH1A1 (0.54) | RAB9ASMN1; SMN2NPC1ALDH1A1POLB | |
| SCHEMBL2559636 | 0.83 | RAB9A (0.64) | RAB9ASMN1; SMN2NPC1ALDH1A1POLB | |
| SCHEMBL6407199 | 0.83 | ALDH1A1 (0.54) | RAB9ASMN1; SMN2NPC1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150209349-A1 | Piperazine Compounds | AMURA THERAPEUTICS LTD (GB) | 2015-07-30 | — | — | US | disclosed |
| US-20150209349-A1 | Piperazine Compounds | AMURA THERAPEUTICS LTD (GB) | 2015-07-30 | — | — | US | disclosed |
| EP-2240491-B1 | TETRAHYDROFURO(2,3-b)PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES | AMURA THERAPEUTICS LTD (GB) | 2015-07-15 | — | — | EP | disclosed |
| US-9045492-B2 | Piperazine compounds | AMURA THERAPEUTICS LIMITED (GB) | 2015-06-02 | — | — | US | disclosed |
| US-9045492-B2 | Piperazine compounds | AMURA THERAPEUTICS LIMITED (GB) | 2015-06-02 | — | — | US | disclosed |
| US-20130252969-A1 | Compounds | AMURA THERAPEUTICS LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130252969-A1 | Compounds | AMURA THERAPEUTICS LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-8501744-B2 | Piperazine compounds | AMURA THERAPEUTICS, LIMITED (GB) | 2013-08-06 | — | — | US | disclosed |
| US-8501744-B2 | Piperazine compounds | AMURA THERAPEUTICS, LIMITED (GB) | 2013-08-06 | — | — | US | disclosed |
| EP-2078023-B1 | TETRAHYDROFURO (3, 2-B) PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES | AMURA THERAPEUTICS LTD (GB) | 2012-12-26 | — | — | EP | disclosed |
| US-20110077254-A1 | COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2011-03-31 | — | — | US | disclosed |
| US-20110077254-A1 | COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2011-03-31 | — | — | US | disclosed |
| US-7799791-B2 | Tetrahydrofuro(3,2-B) pyrrol-3-one derivatives as inhibitors of cysteine proteinases | AMURA THERAPEUTICS LIMITED (GB) | 2010-09-21 | — | — | US | disclosed |
| US-7799791-B2 | Tetrahydrofuro(3,2-B) pyrrol-3-one derivatives as inhibitors of cysteine proteinases | AMURA THERAPEUTICS LIMITED (GB) | 2010-09-21 | — | — | US | disclosed |
| US-20090186831-A1 | Tetrahydrofuro(3,2-B) pyrrol-3-one derivatives as inhibitors of cysteine proteinases | AMURA THERAPEUTICS LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| US-20090186831-A1 | Tetrahydrofuro(3,2-B) pyrrol-3-one derivatives as inhibitors of cysteine proteinases | AMURA THERAPEUTICS LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| WO-2009087379-A2 | TETRAHYDROFURO (3, 2 -B) PYRROL- 3 -ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES | AMURA THERAPEUTICS LIMITED (GB) | 2009-07-16 | — | — | WO | disclosed |
| WO-2008007107-A1 | TETRAHYDROFURO (3, 2-B) PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES | AMURA THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186831-A1 | Tetrahydrofuro(3,2-B) pyrrol-3-one derivatives as inhibitors of cysteine proteinases | TMPRSS6, CCR6, MMP8 | RAB9A 1975/4885SMN1; SMN2 1590/4885NPC1 1985/4885 |
| US-20150209349-A1 | Piperazine Compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHRM1, CHRM5 | RAB9A 365/4885SMN1; SMN2 319/4885NPC1 159/4885 |
| US-20110077254-A1 | COMPOUNDS | CHRM1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PRMT9 | RAB9A 216/4885SMN1; SMN2 312/4885NPC1 82/4885 |
| US-20130252969-A1 | Compounds | CHRM1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PRMT9 | RAB9A 220/4885SMN1; SMN2 318/4885NPC1 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.